Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.74 USD
Change Today -0.02 / -0.35%
Volume 1.2M
ARRY On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 2:40 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

array biopharma inc (ARRY) Snapshot

Open
$5.71
Previous Close
$5.76
Day High
$5.75
Day Low
$5.61
52 Week High
03/5/15 - $8.59
52 Week Low
10/13/14 - $2.98
Market Cap
814.3M
Average Volume 10 Days
1.8M
EPS TTM
$-0.47
Shares Outstanding
141.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARRAY BIOPHARMA INC (ARRY)

array biopharma inc (ARRY) Related Bloomberg News

View More Bloomberg News

array biopharma inc (ARRY) Related Businessweek News

No Related Businessweek News Found

array biopharma inc (ARRY) Details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials include Binimetinib and Encorafenib for the treatment of cancer. Its clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company’s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company’s partnered clinical programs also comprise LY2606368, an Chk-1 inhibitor for cancer; GDC-0575, an Chk-1 inhibitor for cancer; ARRY-380/ONT-380, an HER2 inhibitor for breast cancer,; GDC-0994, an ERK inhibitor for cancer; and LOXO-101, an PanTrk inhibitor for cancer. It has collaborations with Celgene Corporation; Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

198 Employees
Last Reported Date: 08/15/14
Founded in 1998

array biopharma inc (ARRY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $548.8K
Chief Operating Officer
Total Annual Compensation: $343.8K
Compensation as of Fiscal Year 2014.

array biopharma inc (ARRY) Key Developments

AstraZeneca Provides Update on Selumetinib in Uveal Melanoma

AstraZeneca announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing. Selumetinib is a MEK inhibitor in late-stage development, with a primary Phase 3 program in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase 3 study in differentiated thyroid cancer and in a Phase 2 registration study in patients with neurofibromatosis Type 1. Selumetinib is an oral small molecule MEK inhibitor invented by Array BioPharma and licensed to AstraZeneca in 2003. AstraZeneca is responsible for development and commercialization of selumetinib. Selumetinib inhibits the MEK enzyme in the RAS/RAF/MEK/ERK pathway in cancer cells to prevent the tumor from growing. The Selumetinib in Uveal Melanoma Investigator Trial (SUMIT) is a randomized, double-blind, placebo controlled trial being carried out in 45 centers, across 11 countries. Uveal melanoma is an orphan disease in which cancer cells grow in the tissues of the eye. It is the most common primary intraocular malignancy in adults and comprises 5% of all melanomas. There are currently no effective treatments for advanced uveal melanoma and in April 2015, selumetinib was granted Orphan Drug Designation by the US Food and Drug Administration in recognition of the need for new, safe and effective therapies for the disease.

Array Biopharma Announces Encouraging Data from Colorectal Cancer Trials

Array BioPharma Inc. has announced encouraging data from Phase Ib trial and preliminary data from a 100-patient randomized Phase II expansion of that trial, which is testing the combination of encorafenib and cetuximab, an EGFR inhibitor, with or without the addition of alpelisib, an investigational PI3K inhibitor in patients with BRAF-mutant colorectal cancer, or BRAFmut CRC. Results from the study indicate that these combinations can be administered with good tolerability and show promising clinical activity in this patient population with high unmet medical needs. Patient enrollment is now complete in the Phase II study. The preliminary Phase II results show an objective response rate (complete or partial response) and disease control rate (complete or partial response or stable disease) of 29% and 81%, respectively, for patients receiving the combination of encorafenib and cetuximab (encorafenib doublet), and 35% and 79%, respectively, for patients receiving the combination of encorafenib, cetuximab and alpelisib (encorafenib triplet). Across both the encorafenib doublet and triplet treatment groups, most treatment related adverse events were grade 1 or 2 with few grade 3 or 4 adverse events. The most frequent treatment related adverse events across all grades for the encorafenib doublet were fatigue (36%), nausea (31%), lipase increased (24%), diarrhea (21%) and decreased appetite (21%), while for the encorafenib triplet they were diarrhea (39%), nausea (37%), fatigue (33%) and hyperglycemia (31%). These results are consistent with the Phase Ib portion of the trial and are encouraging when compared to currently available therapies for BRAFmut CRC patients, as well as with other recently published investigational approaches in this population. Historically, response rates are very low for either single-agent EGFR or RAF inhibitor therapy in patients with BRAFmut CRC, which suggests a synergistic effect for the combination of encorafenib and cetuximab in this population.

Array BioPharma Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 01:00 PM

Array BioPharma Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 01:00 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Ron Squarer, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARRY:US $5.74 USD -0.02

ARRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $3.90 USD -0.1899
CTI BioPharma Corp $1.86 USD -0.01
Cytokinetics Inc $6.02 USD -1.04
Exelixis Inc $5.53 USD -0.075
Progenics Pharmaceuticals Inc $8.52 USD +0.09
View Industry Companies
 

Industry Analysis

ARRY

Industry Average

Valuation ARRY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.9x
Price/Book 16.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARRAY BIOPHARMA INC, please visit www.arraybiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.